The selective u-opioid agonist, o-Ala*,N-Me-Phe4,Gly5-olenkephalin (DAMGO), or the selective A,-adenosine agonist Ns-cyclopentyladenosine (CPA), when coinjected intradermally with prostaglandin E, (PGE,), dose-dependently inhibited PGE,-induced mechanical hyperalgesia in the rat hindpaw, as determined by the Randall-Selitto paw-withdrawal test. Repeated (hourly x 3) intradermal injections of DAMGO or CPA produced tolerance to the antinociceptive effect of a fourth injection 1 hr later. Furthermore, repeated (hourly x 3) intradermal injections of DAMGO produced cross-tolerance to the antinociceptive effect of CPA, and repeated (hourly x 3) intradermal injection of CPA produced cross-tolerance to the antinociceptive effect of DAM-GO. The demonstration of the bidirectional cross-tolerance between the peripheral antinociceptive effects of DAMGO and CPA supports the hypothesis that both these agents produce antinociception by acting on the same ceil, presumably the primary afferent nociceptor, and that the development of tolerance involves changes downstream to activation of u-opioid and A,-adenosine receptors. The opioid antagonist naloxone, which had no effect on paw-withdrawal threshold in normal paws, produced withdrawal hyperalgesia in DAMGO-tolerant paws. Furthermore, naloxone elicited a cross-withdrawal hyperalgesia response in CPA-tolerant paws. Similarly, the A,-adenosine antagonist 1,3-dipropyl-8-(2-amino-4chlorophenyl)-xanthine (PACPX), which had no effect on paw-withdrawal threshold in normal paws, elicited a withdrawal hyperalgesia response in CPA-tolerant paws and cross-withdrawal hyperalgesia response in DAMGO-tolerant paws. These crossdependence and cross-withdrawal responses suggest that the development of dependence to u-opioid and A,-adenosine agonists involves changes in the same second messenger system downstream to both u-opioid and A,-adenosine receptor activation.
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The systemic administration of opioids produces potent antinociception in animals, and analgesia in humans, by actions both in the dorsal horn of the spinal cord and at supraspinal sites (Mayer and Price, 1976; Duggan, 1979; Fields and Basbaum, 1978) . Clinical and animal studies have shown that opioids also exert antinociceptive effects at peripheral sites in inflamed tissue and inhibit PGE,-induced hyperalgesia (Ferreira and Nakamura, 1979; Smith et al., 1982; Stein et al., 1988 Stein et al., , 1989 Stein et al., , 1991 Levine and Taiwo, 1989; Kayser et al., 1990; Parsons and Herz, 1990; Taiwo and Levine, 1990; Wheeler-Aceto and Cowan, 199 1; Junien and Wettstein, 1992; Moiniche et al., 1993) . There is, at present, a significant interest in the peripheral use of opioids for analgesia, since such use should avoid side-effects (e.g, respiratory depression) that develop to the central action of systemically administered opioids, which often limit their therapeutic use. However, it is not known if peripherally acting opioids would produce tolerance to their analgesic effects which, like for central action, also significantly limits usefulness. Recent experiments have provided some understanding of mechanisms active in opioid tolerance. Most evidence indicates that tolerance to opioid effects in the CNS is due to a functional uncoupling between the opioid receptor and its second messenger, an inhibitory guanosine triphosphate-binding protein (Gprotein), G, (Collin and Cesselin, 1991) , through which opioid agonists act to produce many of their effects (Costa et al., 1988) including antinociception . For example, while chronic opioid exposure does not in general alter opioid binding to its receptor, opioid inhibition of adenylyl cyclase activity is decreased after chronic exposure (Polastron et al., 1990) . In addition, in other in vitro systems chronic administration of morphine results in a loss of the ability of guanine nucleotides to modulate the affinity of the p-opioid receptor for its ligands, associated with a downregulation of high affinity sites (Puttfarcken et al., 1988; Werling et al., 1989) .
A,-Adenosine agonists [such as N+yclopentyladenosine (CPA)], like p-opioids, are able to act in the periphery to inhibit prostaglandin E, (PGE,)-induced hyperalgesia (Taiwo and Levine, 1990) . A,-Adenosine receptors are also coupled to an inhibitory G-protein, and A,-receptor activation also results in inhibition of adenylyl cyclase activity and decreased levels of CAMP (Cooper et al., 1980) . Tolerance at the A,-adenosine receptor occurs following repeated administration of A,-adenosine agonists (Casati et al., 1994; Tsuchida et al., 1994) . However, A,-adenosine receptor-mediated tolerance has not yet been reported with regard to its antinociceptive effects.
In the present study we determined if tolerance develops with regard to the peripheral antinociception produced by a p-opioid or an A,-adenosine agonist. The ability of these agonists to induce cross-tolerance and the ability of opioid and adenosine antagonists to precipitate a withdrawal hyperalgesia was also investigated. Behavioral testing. The nociceptive flexion reflex was quantified with a Basile Analgesymeter (Stoelting, Chicago, IL), which applies a linearly increasing mechanical force to the dorsum of the rat's hindpaw. Rats were trained in the test procedure during the week prior to the experiments, a procedure which produces a stable baseline threshold measurement and enhances the ability to detect the action of hyperalgesic agents . On the day of the experiment, baseline threshold was determined. The mean baseline mechanical nociceptive paw-withdrawal threshold in these experiments was 110.4 + 0.4 gm, n = 340 (mean paw-withdrawal threshold ? SEM). Mechanical threshold was redetermined at different time points (15, 20, and 25 min) after treatments. The mean of these three readings was considered to be the paw-withdrawal threshold following drug administration and this value was used to calculate the percentage change from the baseline threshold.
Drug administration. The drugs used in this study were prostaglandin E, WE,, hyperalgesic inflammatory mediator), o-Ala*,N-MePhe4,GlyS-ol-enkephalin (DAMGO; k-opioid receptor agonist), Nh-cyclopentyl-adenosine (CPA, A,-adenosine receptor agonist), naloxone HCl (opioid receptor antagonist), all from Sigma, St. Louis, MO; 1,3-dipropyl-8-(2.amino-4-chlorophenyl)-xanthine (PACPX, A,-adenosine receptor antagonist) from Research Biochemicals Inc., Natick, MA; and morphine methyliodide (quaternary salt of morphine, which exhibits opioid agonist properties similar to its parent compound, but does not cross the blood brain barrier), a generous gift from Dr. Ivy Carroll, NIDA, Research Triangle Institute. The selection of the drug doses employed in this study was based on dose-response curves determined during this study (DAMGO and CPA) or previously by our laboratory Taiwo and Levine, 1990; Aley et al., 1995) . The stock solution of PGE, (1 kg/2.5 ~1) was prepared in 10% ethanol and further dilutions made in saline. DAMGO, CPA, naloxone, and morphine methyliodide were dissolved in saline. PACPX was dissolved in dimethyl sulfoxide (DMSO, 8 mg/ml) and further dilutions made in saline. Maximum final concentration of ethanol injected was < l%, and the maximum final concentration of DMSO injected was <.5%. All drugs were injected intradermally (i.d.) in a volume of 2.5 p,l/paw. In addition, morphine methyliodide was also injected subcutaneously. When drug combinations were used, they were administered sequentially as indicated from the same syringe. Antagonists were always injected first. Abbreviations for the drugs administered in this study and their actions, are located in Table I .
Experimental protocol. Rats used in this study were divided into different groups; details of drug treatments for each group is given in Table 2 .
Statistical analysis. Data are presented as mean -C SEM of six or more paws in each of the experimental groups. Statistical significance was determined by analysis of variance (ANOVA) followed by Scheffe's post-hoc test; p < 0.05 was considered statistically significant. or CPA were administered hourly for 3 hr in subsequent experiments. When DAM-GO (1 kg) and naloxone (1 kg) were coinjected hourly for 3 hr and at the fourth hour DAMGO plus PGE, was injected, DAM-GO antinociception was not significantly different from that produced by DAMGO in opioid-naive rats ((N+D)x3,D+E2 compared to Dx3,D+E2, p > 0.05; Fig. 2A) ; that is, coinjection of DAMGO with naloxone prevented the development of DAMGO tolerance. Naloxone appears to be acting locally at the site of injection, to inhibit DAMGO antinociception, since DAMGO antinociception is not altered in the paw contralateral to that receiving naloxone (unpublished data). When CPA (1 kg) and PACPX (1 p,g) were coinjected hourly for 3 hr and at the fourth hour CPA plus PGE, was injected, CPA antinociception was not significantly different from that produced by CPA in CPA-naive rats ((PACPX+CPA)x3,CPA+E2 compared to CPAx3,CPA+E2, p > 0.05; Fig. 2B) ; that is, coinjection of PACPX with CPA prevented the development of CPA tolerance.
Results

Inhibition of PGE
Cross-tolerance between DAMGO and CPA antinociception Three hourly injections of DAMGO (1 kg) prior to an injection of CPA plus PGE,, at the fourth hour, significantly blocked CPA antinociception (Dx3,CPA +E2 compared to CPA +E2, (p < 0.05; Fig. 3) ; that is, cross-tolerance developed between DAM-GO and CPA. Similarly, three hourly injections of CPA (1 pg) prior to an injection of DAMGO plus PGE, significantly blocked DAMGO antinociception tested at the fourth hour (CPAx3,D+E2 compared to DiE2, p < 0.05); that is, cross-tolerance developed between CPA and DAMGO.
Effect of naloxone on DAMGO-and CPA-induced tolerance paw-withdrawal threshold of rats treated with three hourly injections of saline vehicle (Vx3,N compared with Vx3, p > 0.05; Fig. 4) .
In rats treated with three hourly injections of DAMGO (1 kg), administration of naloxone at the fourth hour produced a significant decrease in paw-withdrawal threshold (i.e., hyperalgesia) (Dx3,N compared to Dx3, p < 0.05; Fig. 5 ). Similarly, in rats treated with three hourly injections of CPA (1 pg), administration of naloxone at the fourth hour produced a significant decrease in paw-withdrawal threshold (CPAx3,N compared with CPAx3, p < 0.05; Fig. 5 ). In the DAMGO and CPA treated rats, the paw-withdrawal threshold at the fourth hour, prior to the administration of naloxone, was not significantly different from the basal paw-withdrawal threshold (Figs. 5, 7) . Naloxone-induced hyperalgesia in a DAMGO-tolerant paw could be inhibited by coadministration of DAMGO with naloxone at the fourth hour (Dx3,D+N compared to Dx3,N, p < 0,05; Fig. 5 ). Coadministration of CPA with naloxone did not block naloxone-induced hyperalgesia in DAMGO-tolerant paws (Dx3, CPA +N compared with DAMGOx3,N, p > 0.05; Fig. 5 ). In CPA-tolerant Figure   1 . Dose-dependent inhibition of PGE,-induced hyperalgesia by DAMGO and CPA. Effect of PGE, (100 ng, n = 16) on paw-withdrawal thresholds and its modification by different doses of: A, DAMGO (n = 6), or B, CPA (n = 6). In this and subsequent figures where no error bars seen, they are contained within the symbols. Figure 2 . Time course for the development of tolerance to DAMGOand CPA-induced antinociception and the blockade of the development of tolerance by coadministration of specific receptor antagonists. '4, Effect of different number of preceding hourly doses of DAMGO (D) (1 pg) on DAMGO inhibition of PGE, hyperalgesia (Dx2,D +E2 = DAM-GO hourly X 2, then DAMGO plus PGE, at the next hour, and similarly for 3 and 4 hr). Naloxone plus DAMGO hourly X 3 and at the fourth hour DAMGO plus PGE, (N +Dx3, D +E2, n = 6). B, Effect of different number of preceding hourly doses of CPA (CPA) (1 bg) on CPA inhibition of PGE, hyperalgesia (CPAx2, CPA +E2 = CPA hourly X 2, then CPA plus PGE, at the next hour, and similarly for 3 and 4 hr). PACPX plus CPA hourly X 3 and at the fourth hour CPA plus PGE, (PACPXKPAx3,CPA tE2, n = 6). 
Effects qf PACPX on CPA-and DAMGO-induced tolerance
The A,-adenosine antagonist PACPX (1 kg) blocked CPA antinociception (PACPX+CPA+E2 compared to CPA+E2, p < 0.05; Fig. 6 ), but not DAMGO antinociception (PACPX+D tE2 compared to D+E2, p > 0.05; Fig. 6 ); that is, CPA but not DAMGO is acting at the A,-adenosine receptor. Three injections of CPA (1 pg), one every hour, had no significant effect on paw-withdrawal threshold (CPAx3 compared to Vx3, p > 0;05; Fig. 6 ). PACPX (1 pg) also did not have a significant effect on the paw-withdrawal threshold of rats treated with three hourly injections of saline vehicle (Vx3,PACPX compared to Vx3, p > 0.05; Fig. 6 ).
In rats treated with three hourly injections of CPA (1 pg), administration of PACPX at the fourth hour produced a significant decrease in paw-withdrawal threshold (i.e., hyperalgesia) (CPAx3,PACPX compared to CPAx3, p < 0.05, Figs. 7). Similarly, after three hourly injections of DAMGO (1 pg), administration of PACPX at the fourth hour produced a significant decrease in paw-withdrawal threshold (i.e., hyperalgesia) (Dx3,PACPX, compared to Dx3, p < 0.05; Fig. 7 Figure   3 . Bidirectional cross-tolerance develops between DAMGOand CPA-induced antinociception. Effect of PGE, (E2, n = 16); DAM-GO hourly X 3 and at the fourth hour CPA plus PGE, (Dx3, CPA +E2, IZ = 10) compared to DAMGO and PGE, (D+E2, n = 16); and CPA hourly X 3 and at the fourth hour DAMGO plus PGE, (CPAx3,D+E2, IZ = 10) compared to CPA plus PGE, (CPA +E2, n = IO) on mechanical paw-withdrawal threshold in the rat. (Figs. 5, 7) . PACPX-induced withdrawal hyperalgesia could be inhibited by coadministration of CPA with PACPX at the fourth hour (CPAx3,CPA +PACPX compared to Dx3,PACPX, p < 0.05; Fig. 7 ). However, coadministration of DAMGO with PACPX did not block PACPX-induced withdrawal hyperalgesia in CPA-tolerant paws (CPAx3,D+PACPX compared to CPAx3,PACPX, p > 0.05). In DAMGO-tolerant paws coadministration of DAMGO with PACPX did not block PACPX-induced withdrawal hyperalgesia (Dx3,D+PACPX, compared to Dx3, p < 0.05; Fig. 7) . However, in DAMGO-tolerant paws CPA did block PACPX-induced withdrawal hyperalgesia (Dx3,CPA+PACPX compared to Dx3,PACPX, p < 0.05; Fig.   7 ).
Effect of morphine methyliodide on PGE,-hyperalgesia
To confirm that the antinociceptive effect of intradermally administered opioid was due to its peripheral action, the effect of a quaternary salt of morphine on PGE,-induced hyperalgesia was evaluated. Morphine methyliodide (MMI) (10 and 100 pg) was antinociceptive (E2 compared with MMI(IOpg) +E2 and E2 compared to MMI(ZOO& +E2, both p < 0.05, Fig. 8 ). However, subcutaneous (in the neck) injection of morphine methyliodide failed to inhibit PGE,-induced hyperalgesia (100 pg, MMZ(ZOOpg,SC)+E2 compared to E2) (p > 0.05).
P<O.O5 Figure 4 . Naloxone blocks DAMGObut not CPA-induced antinociception. Effect of PGE, (E2, IZ = 16), DAMGO and PGE, (D+E2, n = 16), naloxone, DAMGO and PGE, (N+D+E2, n = 6), CPA and PGE, (CPA tE2, n = I2), naloxone, CPA and PGE, (NKPA +E2, II = 6), DAMGO hourly X 3 (Dx3, n = 14), Saline (2.5 IJ-l/paw) hourly X 3 (Sx3, n = 6), saline (2.5 pJpaw) hourly X 3 and at the fourth hour naloxone (Vx3,N, n = 6).
Discussion
In this study, we found that tolerance develops to the peripheral antinociceptive effects of DAMGO and CPA after repeated administration of these agents in the hindpaw of the rat. Since the development of tolerance is blocked by coadministration of naloxone (but not PACPX) with DAMGO or of PACPX with CPA (but not DAMGO), we suggest that DAMGO is acting at an opioid receptor (presumably p,) and CPA is acting at an A,-adenosine receptor to produce tolerance. In a previous study, repeated subcutaneous (i.e., systemic) administration of morphine failed to produce tolerance to the antinociceptive activity of intraplantar (i.e., local peripheral) morphine administration (Ferreira et al., 1984) . The lack of observed tolerance to peripheral morphine in that study may be due to the difference in the route of drug administration used to induce tolerance compared to our study. Following injection into the hindpaw, DAMGO and CPA probably exert their antinociceptive effects locally, since the doses administered are too low to have an effect in the CNS (Taiwo and Levine, 1990) . This hypothesis is supported by the observation that the quaternary compound morphine methyliodide, which does not as readily enter the CNS, produced antinociception following intradermal administration into the hindpaw, but not when the same dose was administered systemically (subcutaneously at a distant site). . Naloxone induces withdrawal hyperalgesia in DAMGO-and CPA-tolerant paws. Effect of DAMGO hourly X 3 and at the fourth hour naloxone (DxJ,N, II = 18), CPA hourly X 3 and at the fourth hour naloxone (CPAx3,N, n = 6), DAMGO hourly X 3 and at the fourth hour DAMGO plus naloxone (Dx3, D +N, n = 6), DAMGO hourly X 3 and at the fourth hour CPA plus naloxone (Dx3, CPA +N, n = 12), CPA hourly X 3 and at the fourth hour DAMGO plus naloxone (CPAx3,D +N, n = 6), and CPA hourly X 3 and at the fourth hour CPA plus naloxone (CPAx3, CPA +N, n = 8) on mechanical paw-withdrawal threshold in the rat. 
n = 6). CPA hourlv x 3 (CPAx3, n = lo), saline (2.5 pi) hourly X 3 (Sx3, II = 6), saline (2.5 pl/ paw) hourly X 3 and at the fourth hour PACPX (Vx3,PACPX, n = 6). and CPA suggests that opioid and A,-adenosine receptors on the same cell, possibly the primary afferent nociceptor, and are coupled to a common second messenger system that participates in the development of tolerance. There is now considerable evidence that CAMP mediates the hyperalgesic effects of PGE, (Ferreira and Nakamura, 1979; Taiwo and Levine, 1991; Hingtgen et al., 1995) as well as a sensitization of primary afferent neurons (Pitchford and Levine, 1991; Vasko et al., 1994; Wang et al., 1995) . For example, PGE, raises immunoreactive CAMP levels in sensory neuron cultures, which results in an enhanced release of primary afferent neurotransmitter peptides (evoked by bradykinin or capsaicin) (Hingtgen et al., 1995) . Increased CAMP levels will also produce an increase in the phosphorylation of intracellular proteins, including ion channels, thereby increasing neuronal excitability. In fact, several studies have demonstrated that both CAMP and prostaglandins enhance sensory neuron excitation produced by bradykinin or capsaicin (Martin et al., 1987; Dray et al., 1992; Ouseph et al., 1995) . Therefore, it is of note that it has been shown that both opioids and A,-adenosine antinociceptive agents act on receptors coupled to G-proteins (Ferreira, 1981; Taiwo and Levine, 1991; Ingram and Williams, 1994) which decrease CAMP levels (VanCaulker et al., 1979; Hamprecht and VanCaulker, 1985) . These results suggest that primary afferent induced hyperalgesia Figure   7 . PACPX induces withdrawal hyperalgesia in CPA-and DAMGOtolerant paws. Effect of CPA hourlv X 3 and at the fourth hour PACPX (CPAx3,PACPX. n = 8). DAMGO hourlv X 3 and at the 'fourth hour PACPX (Dx3,PACPX, n = 8), CPA hourly X 3 and at the fourth hour CPA plus PACPX (CPAx3, CPA +PACPX, n = 6), CPA hourly X 3 and at the fourth hour DAMGO plus PACPX (CPAx3,D+PACPX, n = 6), DAMGO hourly X 3 and at the fourth hour DAMGO DlUS PACPX (Dd.D+PACPX. n = 6), DAMGO hourly X'3 and at the fourth hour CPA plus PACPX (Dx3,CPA +PACPX, n = 6) on mechanical paw-withdrawal threshold in the rat. and antinociception involve modulation of a common second messenger pathway (Hingtgen et al., 1995) .
An alternative explanation for the observed cross-tolerance is that repeated DAMGO administration could release endogenous adenosine (to act at and tolerize A,-receptors).
This alternative explanation is unlikely for two reasons. First, while endogenous opioids can be released in peripheral tissues, this only occurs in the setting of inflammation (Stein et al., 1990) , and opioids, such as DAMGO, are anti-inflammatory in peripheral tissues. Second, since PACPX did not affect DAMGO antinociception (suggesting endogenous adenosine is not involved) and naloxone did not affect CPA antinociception (suggesting that endogenous opioids are not involved), it is unlikely that cross-tolerance between DAMGO and CPA is due to release of endogenous ligands. Tolerance to the effects of opioids is commonly associated with the development of dependence on the opioid, most often evident by the presence of an abstinence-induced or an antagonist-precipitated withdrawal (Way, 1993) . For example, after development of tolerance to the antinociceptive effect of morphine, hyperalgesia might result if the opioid is discontinued or if naloxone were administered. We found that both in DAMGOand CPA-tolerant paws, a withdrawal response is induced by the selective opioid and A,-adenosine antagonists respectively, and also that a cross-withdrawal response is observed (Figs. 5, 7 ). Antagonist-induced withdrawal is thought to result from displacement of the agonist from its receptor binding sites. However, the observation of cross-withdrawal suggests that dependence in this model is not maintained'solely by receptor occu- Figure   8 . Quaternary morphine inhibits PGE,-induced hyperalgesia. Effect of PGE, (E2, n = 16), morphine methyliodide (10 pg) plus PGE, (MMZ(lOpg) +E2, n = 6), morphine methyliodide (100 kg) plus PGE, (MMI(/O@gj tE2, n = 6), and morphine methyliodide 100 p,g S.C. plus PGE, (MMl(lOO~g,SC)+E2, n = 6) on mechanical paw-withdrawal threshold in the rat.
panty. A recent model of opioid dependence suggested by Wang and colleagues (1994) is of interest in this regard. These workers hypothesize that p-opioid agonists produce dependence by inducing a spontaneously active phosphorylated state of the p-opioid receptor at which naloxone can act as an inverse agonist. Thus, cross-tolerance may be a result of phosphorylation of both the A,-adenosine as well as the p,-opioid receptor following chronic exposure to either CPA or DAMGO.
DAMGO failed to block PACPX-induced withdrawal hyperalgesia in DAMGO-tolerant paws (Fig. 7) . Similarly, CPA administered with naloxone in CPA-tolerant paws resulted in a marked naloxone-induced cross-withdrawal (Fig. 5) ; however, there was a small, but statistically significant, reduction compared to naloxone alone. This small difference may be due to an incomplete tolerance for CPA agonism produced following three hourly injections.
In conclusion, we report that both p-opioid and A,-adenosine agonists produce tolerance to their peripheral antinociceptive effects on repeated administration. Furthermore, we suggest that both p-opioid and A,-adenosine receptors share a common second messenger pathway in the induction of tolerance since there is cross-tolerance between agonists acting at these two receptors. Finally the observation of naloxone-and PACPX-induced withdrawal in both opioid-and CPA-tolerant paws, supports the hypothesis of the development of a cross-dependence as well as a cross-tolerance for the peripheral antinociceptive effects of F-opioid and A,-adenosine agonists. The failure of the opioid agonist to block the withdrawal effect of the A,-adenosine antagonist and the failure of the adenosine agonist to block the withdrawal effect of opioid antagonist, irrespective of the agonist (k or A,) used to induce tolerance, suggests that it is not necessary for an agonist to occupy a receptor for an antagonist to be able to precipitate withdrawal and thus that there must be changes in the action of the antagonist at that receptor (e.g., phosphorylation of the receptor so that the antagonist can now act as an inverse agonist ; Wang et .al., 1994) . This suggests that the changes associated with dependence may involve cellular mechanisms distinct from those underlying tolerance. Further studies are in progress to investigate the specific second messenger pathways in the primary afferent underlying these phenomena.
